DMEM高糖培養(yǎng)基粉末含丙酮酸鈉Gibco操作步驟儲(chǔ)存條件：避光、干燥陰涼處封閉貯存,嚴(yán)禁與有毒、有害物品混放、混運(yùn)。本品為非危險(xiǎn) 產(chǎn)品可按一般化學(xué)品運(yùn)輸,輕搬動(dòng)輕放,防止日曬、雨淋！受熱、受潮、受光后易喪失活力,保存期短,因此貯存和運(yùn)輸條件比較苛刻。
產(chǎn)品名稱：DMEM高糖培養(yǎng)基粉末含丙酮酸鈉Gibco操作步驟
英文名字：DMEM, Powder, High Glucose, Pyruvate (Gibco)
物理性狀及規(guī)格：
谷氨酸鹽:…………………L-谷氨酸
酚紅指示劑:………………含酚紅
形態(tài):………………………粉末
葡萄糖:……………………高濃度葡萄糖
HEPES 緩沖液:…………不含HEPES
丙酮酸鈉添加劑:…………丙酮酸鈉
碳酸氫鈉緩沖溶液:………不含碳酸氫鈉
用途及描述：
Dulbecco's Modified Eagle Medium (DMEM) is a widely used basal medium for supporting the growth of many different mammalian cells. Cells successfully cultured in DMEM include primary fibroblasts, neurons, glial cells, HUVECs, and smooth muscle cells, as well as cell lines such as HeLa, 293, Cos-7, and PC-12.
儲(chǔ)存條件：冰袋運(yùn)輸，防潮密閉干燥。
DMEM高糖培養(yǎng)基粉末含丙酮酸鈉Gibco操作步驟儲(chǔ)存條件：
大部分的試劑產(chǎn)品是比較穩(wěn)定的，只要您嚴(yán)格按照產(chǎn)品包裝或者說明書上的儲(chǔ)存條件進(jìn)行儲(chǔ)存，*可以保證其在有效期內(nèi)的正常使用。一般常見儲(chǔ)存條件有零下XX攝氏度，2-8攝氏度，常溫等。特別提醒，對于某些酶類制品，如果儲(chǔ)存條件是2-8攝氏度，不要儲(chǔ)存在零下，否則容易失活，對于某些需要嚴(yán)格避光，防潮，充氮?dú)獗Ｗo(hù)的，接觸空氣或者過分暴露非常容易氧化或者受潮變質(zhì)。
低溫儲(chǔ)存產(chǎn)品，運(yùn)輸途中冷藏問題：
對于需要低溫儲(chǔ)存的產(chǎn)品，我們在運(yùn)輸時(shí)候都會(huì)采用冷藏包裝，但是部分由于外界氣溫過高，運(yùn)輸時(shí)間較長，對于普通冷藏包裝，途中可能會(huì)溫度升高，這些都是沒有問題的，因?yàn)檫@種普通冷藏只適用于那些短期內(nèi)（2周）高溫依然穩(wěn)定的產(chǎn)品，建議低溫的儲(chǔ)存條件，只是長期儲(chǔ)存時(shí)候的條件，您可以放心使用。對于某些特殊的產(chǎn)品，如抗體，我們會(huì)采用干冰冷藏包裝，確保全程低溫。公司都對產(chǎn)品性狀進(jìn)行了嚴(yán)格的加速穩(wěn)定測試，行業(yè)經(jīng)驗(yàn)豐富。
DMEM高糖培養(yǎng)基粉末含丙酮酸鈉Gibco操作步驟產(chǎn)品應(yīng)用：
對于一些相對特殊的產(chǎn)品，我們會(huì)提供產(chǎn)品說明書，里面會(huì)對產(chǎn)品溶解性，及我們所能了解的產(chǎn)品應(yīng)用信息，實(shí)驗(yàn)方案進(jìn)行描述，您可以作為參考。對于常見試劑，因?yàn)閼?yīng)用廣泛，一般不提供說明書。如果您在實(shí)驗(yàn)過程中遇到了問題，歡迎與我們討論，我們將盡力幫您解決。
DMEM高糖培養(yǎng)基粉末含丙酮酸鈉Gibco操作步驟分裝及溶液配制：
您收到貨物后不要自己進(jìn)行分包，因?yàn)榉职h(huán)境、包裝材料等因素可能導(dǎo)致分包后的產(chǎn)品變質(zhì)；如您有特殊包裝要求，請?jiān)谟嗁彆r(shí)候與我們客服代表闡明，當(dāng)然價(jià)格會(huì)做適當(dāng)調(diào)整。對于開蓋后，長期未使用的，請務(wù)必重新密封好，建議Parafilm封口膜，并按照相應(yīng)儲(chǔ)存條件使用。如果放置時(shí)間過長，超過產(chǎn)品有效期，建議您重新購買，以免影響實(shí)驗(yàn)質(zhì)量。
CFN98371 http://www.chemfaces。。ｃｏｍ/natural/Astilbin-CFN98371.html C21H22O11 450.4 29838-67-3 Astilbin Flavonoids >=98% 20mg
CFN98178 http://www.chemfaces。。ｃｏｍ/natural/4-Acetoxycinnamic-acid-CFN98178.html C11H10O4 206.19 15486-19-8 4-Acetoxycinnamic acid Phenylpropanoids >=98% 100mg
CFN98179 http://www.chemfaces。。ｃｏｍ/natural/p-Hydroxy-cinnamic-acid-CFN98179.html C9H8O3 164.16 7400-08-0 p-Hydroxy-cinnamic acid Phenylpropanoids >=98% 20mg
CFN98180 http://www.chemfaces。。ｃｏｍ/natural/Ethyl-4-methoxycinnamate-CFN98180.html C12H14O3 206.24 24393-56-4 Ethyl 4-methoxycinnamate Phenylpropanoids >=98% 100mg
CFN98385 http://www.chemfaces。。ｃｏｍ/natural/Harmaline-CFN98385.html C13H14N2O 214.3 304-21-2 Harmaline Alkaloids > 98% 20mg
CFN98391 http://www.chemfaces。。ｃｏｍ/natural/Magnolin-CFN98391.html C23H28O7 416.5 31008-18-1 Magnolin Lignans > 98% 20mg
CFN98181 http://www.chemfaces。。ｃｏｍ/natural/trans-3-Hydroxycinnamic-acid-CFN98181.html C9H8O3 164.16 14755-02-3 trans-3-Hydroxycinnamic acid Phenylpropanoids >=99% 100mg
CFN98182 http://www.chemfaces。。ｃｏｍ/natural/3-4-5-Trimethoxycinnamic-acid-CFN98182.html C12H14O5 238.24 90-50-6 3,4,5-Trimethoxycinnamic acid Phenylpropanoids >=98% 100mg
CFN98183 http://www.chemfaces。。ｃｏｍ/natural/4--Dimethylamino-cinnamic-acid-CFN98183.html C11H13NO2 191.23 1552-96-1 4-(Dimethylamino)cinnamic acid Alkaloids >=99% 100mg
CFN98184 http://www.chemfaces。。ｃｏｍ/natural/4-Chlorocinnamic-acid-CFN98184.html C9H7ClO2 182.60 1615-02-7 4-Chlorocinnamic acid Phenylpropanoids >=99% 100mg fibrinolysis.
Subunit : Forms protease inhibiting heterodimer with TMPRSS7. Interacts with VTN. Binds LRP1B; binding is followed by internalization and degradation.
Subcellular Location : Secreted
Tissue Specificity : Found in plasma and plaets and in endothelial, hepatoma and fibrosarcoma cells
Post-translational modifications : Inactivated by proteolytic attack of the urokinase-type (u-PA) and the tissue-type (TPA), cleaving the 369-Arg-|-Met-370 bond.
DISEASE : Plasminogen activator inhibitor-1 deficiency (PAI-1D) [MIM:613329]: A hematologic disorder characterized by increased bleeding after trauma, injury, or surgery. Affected females have menorrhagia. The bleeding defect is due to increased fibrinolysis of fibrin blood clots due to deficiency of plasminogen activator inhibitor-1, which inhibits tissue and urinary activators of plasminogen. Note=The disease is caused by mutations affecting the gene represented in this entry.
DMEM高糖培養(yǎng)基粉末含丙酮酸鈉Gibco操作步驟Note=High concentrations of SERPINE1 seem to contribute to the development of venous but not arterial occlusions.
Similarity : Belongs to the serpin family
Database links : UniProtKB/Swiss-Prot: P05121.1
